Cellectar Biosciences CLRB 深 沪
已收盘 08-07 16:00:00 美东时间
2.57
+0.050
+1.98%
华盛通- 最 高2.5899
- 今 开2.52
- 成交量 1.61万股
- 最 低 2.49
- 昨 收 2.52
- 总市值 2053.90万
- 52周最高 6.52
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 2.20
- 委 比 -32.45%
- 总股本 799.18万
- 历史最高 276000.00
- 量 比 0.31
- 振 幅 3.96%
- 历史最低 2.20
- 每 手 1
- 风险率 0.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectar Biosciences Announces Publication Of Results From Phase 1 Dose-Escalation Study Evaluating Iopofosine I 131 In Combination With Low-Dose Dexamethasone In 31 Patients With Heavily Pretreated R/R MM
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiotherapeutic Across Multiple B-Cell Malignancies FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) ...
07-15 19:33
Cellectar Biosciences Shareholders Approve Key Governance Measures
An announcement from Cellectar Biosciences ( ($CLRB) ) is now available. At its...
07-11 05:28
Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCO
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyPlans to Initiate Phase 3 Confirmatory
06-01 20:15
Cellectar Biosciences Bets on Iopofosine Breakthrough
Cellectar Biosciences Inc (($CLRB)) has held its Q1 earnings call. Read on for ...
05-20 13:19
Cellectar Biosciences Announces Board Changes and New Director
The latest announcement is out from Cellectar Biosciences ( ($CLRB) ). On May 1...
05-19 06:01
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10
Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.
05-16 03:31
Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call
Cellectar Biosciences (NASDAQ:CLRB) reported first-quarter financial results on...
05-14 20:59
